Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Ondansetron Slightly Prolongs QTc Interval in Pediatrics Without Dysrhythmia Risk

Key Takeaway
Prescribe ondansetron without dysrhythmia concern in healthy pediatric patients.

This meta-analysis evaluated the impact of low-dose ondansetron on electrocardiographic changes in healthy pediatric patients. The analysis included four studies with a total of 231 participants, predominantly male, aged 0.6 to 18 years. Ondansetron was administered either intravenously or orally, with doses ranging from 0.1 to 0.2 mg/kg for IV and a mean of 0.18 mg/kg for oral administration, not exceeding 8 mg. The primary endpoint was the mean change in the corrected QT interval (QTc), which showed a statistically significant increase of 4.7 ms (95% CI 1.4-8.1). Secondary endpoints included the mean change in the Tp-e interval, which increased by 7.7 ms (95% CI 2.0-13.5), and the incidence of significant QTc prolongation, which was 2.5% (95% CI -0.009-0.059). Importantly, no cardiac dysrhythmias were observed in any of the studies. These findings suggest that while ondansetron administration is associated with a slight prolongation of the QTc and Tp-e intervals, it does not increase the risk of cardiac dysrhythmias in healthy pediatric patients. Clinicians can consider these results reassuring when prescribing low-dose ondansetron in this population, although continued monitoring of QTc intervals may be prudent.

AI Accuracy Review: 10/10 · Auto-published
View Original Abstract ↓
OBJECTIVE: The aim of this study was to describe electrocardiographic changes in healthy pediatric patients receiving low-dose ondansetron and to determine whether these changes are associated with the occurrence of cardiac dysrhythmias. DATA SOURCE: The search was conducted in PubMed, EMBASE, LILACS, SciELO, and the Cochrane databases, selecting articles published until September 2024. The primary outcome was the mean change in the corrected QT interval (QTc) interval. The mean variation of the Tp-e interval and the incidence of significant QTc prolongation were assessed as secondary outcomes. DATA SYNTHESIS: Four studies were included in this review, including 231 healthy pediatric patients who received ondansetron (IV or oral). Most were male, aged 0.6-18 years. The mean IV ondansetron dose ranged from 0.1 to 0.2 mg/kg, while the mean oral dose was 0.18 mg/kg, with a maximum dose of 8 mg. The mean change in the QTc interval was 4.7 ms (95% confidence interval [CI] 1.48.1), and in the Tp-e interval was 7.7 ms (95%CI 2.0-13.5). The risk of a significant QTc prolongation was 2.5% (95%CI -0.009-0.059). No dysrhythmia was observed in the studies. CONCLUSIONS: There was a statistically significant increase in QTc and Tp-e intervals following ondansetron administration in healthy pediatric patients. However, it is highly unlikely that these changes result in cardiac dysrhythmia, suggesting no relationship between low-dose ondansetron use and an increased risk of dysrhythmia in healthy pediatric patients.
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…